CoRegen, a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, announced the close of a $93,390,000 million financing.

The proceeds from this round will be used to advance CoRegen's chemistry, manufacturing, and controls (CMC) development, initiate a Phase 1/2 clinical trial for its steroid receptor coactivator 3 knock-out Regulatory T (Treg) cells (SRC3-KO) program in patients with various solid-tumor types in the first half of 2026 and expand its leadership team with key hires to drive execution and support the company's growth.